Malignant prolactinoma.
Malignant prolactinoma is a rare entity and only a few cases have been published. The diagnostic criteria and the clinical course remain unclear. We present a case of malignant prolactinoma in a woman with a 30-year duration of the disease. In the terminal stage of the disease the prolactinoma metastasized to the left eye, the prolactin level reaching 196000 mU/l. Bromocriptine in high doses was not effective. The response to pergolide was good in the first two years of treatment; thereafter an escape effect was observed. The patient died in a comatose state. A review of previously published cases follows.
Berezin
M
M
Institute of Endocrinology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Gutman
I
I
Tadmor
R
R
Horowitz
A
A
Findler
G
G
D001971:Bromocriptine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009918:Orbital Neoplasms / Q000097:blood / Q000556:secondary / Q000628:therapy; D010479:Pergolide / Q000627:therapeutic use; D010911:Pituitary Neoplasms / Q000097:blood / Q000473:pathology / Q000628:therapy; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000097:blood / Q000556:secondary / Q000628:therapy
D010479:Pergolide; D001971:Bromocriptine; D011388:Prolactin